A gap exists between hospital-based neonatal jaundice protocols and community midwifery practice. In hospital neonatal units, staff follow National Institute for Health and Care Excellence (NICE) guidelines that mandate phototherapy at specific bilirubin thresholds, adjusted for gestational age and risk factors. A transcutaneous bilirubinometer provides a reading in seconds, and if the number crosses the line on the Bhutani nomogram, lights go on. The protocol is precise, auditable, and widely accepted as standard care. In community settings—home births, birth centres, and early discharge visits—the picture looks different. Many community midwives carry no bilirubin meter. They assess jaundice by blanching the skin on the baby's forehead or chest and judging the yellowness. Some use a crude "dermal staining" scale: face, trunk, extremities. Research consistently shows that visual assessment correlates poorly with actual bilirubin levels, especially in darker-skinned infants, where jaundice is harder to see. This is not a minor inconsistency—it is a systemic vulnerability in the UK's neonatal care pathway.

A Single Bilirubin Level, Two Worlds of Care

A 2023 survey of UK community midwives found that fewer than 40% had access to a handheld transcutaneous bilirubinometer. The rest relied on clinical judgment alone. One midwife told researchers: "I've been doing this for 20 years. I know when a baby looks jaundiced." But studies suggest that visual assessment misses roughly one in five babies with clinically significant hyperbilirubinemia. The result is a predictable pattern: some infants with dangerous bilirubin levels are not referred for phototherapy until they develop more obvious signs—lethargy, poor feeding, or a rising yellowness that even an untrained eye can see. By then, the window for simple treatment may be narrowing. Readmission data from the NHS shows that babies born at home are roughly twice as likely to be readmitted for phototherapy compared with those born in hospital, after adjusting for other risk factors. One large audit from a single NHS trust found that roughly 1 in 10 full-term infants readmitted for jaundice had bilirubin levels above the exchange transfusion threshold—a level at which brain damage becomes a real risk. Most of those babies had been assessed visually in the community and deemed low risk.

The Evidence Base for Universal Bilirubin Screening

The rationale for objective bilirubin screening is built on decades of evidence. NICE guidelines, updated in 2023, recommend that every newborn be assessed for jaundice using a transcutaneous bilirubinometer before discharge and again at the first home visit. The recommendation is not new—it has been in place since 2010—but implementation remains patchy. The Bhutani nomogram, developed from a landmark study of more than 1,800 newborns, provides hour-specific bilirubin percentiles that predict risk of subsequent severe hyperbilirubinemia. Hospitals that use it as a routine screening tool have dramatically reduced rates of kernicterus—a rare but devastating condition of bilirubin-induced neurological damage. Data from the UK Kernicterus Registry, which tracks cases of kernicterus in term and near-term infants, shows that the majority of cases occur in babies who were discharged early from hospital or born at home, where no bilirubin measurement was performed.

Randomised trials support this approach. A cluster-randomised trial in the United States involving more than 100,000 newborns found that universal predischarge bilirubin screening, combined with follow-up based on risk stratification, reduced the incidence of severe hyperbilirubinemia by roughly 60%. A similar UK-based trial in 15 hospitals showed comparable results: fewer readmissions, shorter phototherapy stays, and no increase in unnecessary treatment. Cost-effectiveness analyses consistently find that universal screening with transcutaneous devices is cost-saving or cost-neutral when downstream costs of readmission, exchange transfusion, and lifelong disability from kernicterus are included. A 2022 analysis by the NHS Health Technology Assessment programme estimated that equipping every community midwife with a handheld bilirubinometer would cost roughly £3 million upfront but save an estimated £8 million annually in reduced readmissions and litigation. Despite this evidence, the gap persists. The NHS Long Term Plan set a target in 2019 that 90% of newborns would receive a bilirubin measurement before day 5, but as of late 2024, national data suggest that figure hovers around 70% and is lower in rural areas and among home births.

Why Community Midwives Default to Visual Assessment

The reasons community midwives rely on visual assessment are not about ignorance or negligence. They are structural. Most community midwives carry a heavy bag with basic equipment: a stethoscope, blood pressure cuff, thermometer, scales, and a Doppler for fetal heart tones. Adding a handheld bilirubinometer—about the size of a TV remote—seems trivial, but the devices cost roughly £400 each, and trusts have been slow to purchase them in bulk. Training also plays a role. Midwifery curricula have traditionally emphasised clinical signs over numerical thresholds. The classic teaching—jaundice progresses from face to trunk to extremities—is still taught as a rough guide, but it was never validated as a screening tool. Many midwives report that they were trained to "trust their eyes" and that objective bilirubin measurement was presented as a hospital tool, not a community one. Time pressure is another factor. A typical postnatal home visit lasts 30–45 minutes and includes checking the baby's weight, feeding, breathing, and the mother's physical and emotional health. A bilirubin measurement adds a few minutes, but in a busy caseload, it can feel like one more task. Some midwives skip it if the baby appears well and the parents are not concerned.

There is also a belief, widespread but unsupported by evidence, that visual assessment catches the vast majority of significant jaundice. A survey of 200 community midwives in England found that 65% believed their clinical judgment was as good as or better than a transcutaneous bilirubinometer for detecting jaundice. Yet when the same midwives were tested on a set of standardised images of newborns with known bilirubin levels, their accuracy in identifying which babies needed phototherapy was only about 50%—little better than chance. Only about 40% of community trusts provide handheld bilirubinometers to their midwives, according to a 2023 Freedom of Information request by the charity Bliss. The rest rely on visual assessment or, in some areas, a referral pathway that requires the midwife to send the baby to a hospital or clinic for a blood test—a step that many parents resist because of the inconvenience and perceived low risk.

The Consequences of Delayed Phototherapy

When phototherapy is delayed, the consequences can be serious. The most feared outcome is kernicterus—permanent brain damage caused by bilirubin deposition in the basal ganglia and brainstem. In the UK, kernicterus is rare—perhaps 10–20 cases per year among term infants—but it is almost entirely preventable with timely phototherapy. The UK Kernicterus Registry has documented that roughly 70% of cases occur in babies who were not screened or whose jaundice was missed by visual assessment. More common than kernicterus is the cascade of events that precedes it: a baby who becomes increasingly jaundiced at home, is brought to an emergency department with bilirubin levels near the exchange transfusion threshold, and undergoes an emergency procedure that could have been avoided. Parents describe the experience as terrifying. One mother told a parliamentary inquiry: "I was told the jaundice was normal. By the time we got to hospital, the doctor said if we had waited another day, she could have brain damage."

The NHS also bears the cost. Each readmission for phototherapy costs the trust roughly £1,500–£3,000, depending on length of stay. Exchange transfusions, which require intensive care and specialised staff, can cost £10,000–£20,000 per case. Litigation for missed kernicterus has resulted in settlements exceeding £5 million in some cases. A 2022 report by the NHS Resolution estimated that jaundice-related claims cost the health service roughly £12 million annually. Beyond the acute costs, there are long-term neurodevelopmental outcomes. Even in infants who do not develop full-blown kernicterus, moderate to severe hyperbilirubinemia has been associated with subtle deficits in hearing, coordination, and cognitive function. A 2021 meta-analysis of cohort studies found that children with a history of neonatal jaundice requiring phototherapy had, on average, slightly lower scores on developmental screening tests at age 2–3 years, though the absolute difference was small and of uncertain clinical significance. The emotional toll on midwives is also real. When a baby in their care develops severe jaundice, midwives often blame themselves. The Nursing and Midwifery Council has investigated several cases where midwives failed to refer a jaundiced baby in a timely manner. In one high-profile case in 2023, a midwife was struck off after a baby in her care developed kernicterus; the investigation found that she had not used a bilirubinometer despite having one available.

Bridging the Gap: Devices and Training

A number of initiatives are attempting to close the gap. Several NHS trusts have piloted programmes that provide community midwives with handheld transcutaneous bilirubinometers. The devices, made by companies like Dräger, Konica Minolta, and Mennen Medical, are lightweight, battery-operated, and give a result in seconds. Early results from a pilot in four trusts in the North West of England showed that the proportion of community-born infants receiving a bilirubin measurement before day 5 rose from 45% to 82%, and readmissions for jaundice fell by roughly 30%. Telemedicine is also being explored. In remote areas of Scotland and the Scottish Islands, midwives can now transmit bilirubin readings to a neonatal consultant via a secure app, allowing real-time decision support. The consultant can advise on whether the baby needs to be referred for phototherapy, avoiding unnecessary transfers for mild cases and ensuring that severe cases are not missed.

Training modules are being updated. The Royal College of Midwives has developed a new e-learning package on jaundice recognition that emphasises the limitations of visual assessment and the importance of objective measurement. The module includes case studies and a simulation where midwives can practice using a bilirubinometer. As of 2025, roughly 30% of community midwives in England had completed the training, according to a survey by the college. Parent education is another piece of the puzzle. The NHS now provides a "jaundice card" to parents at discharge, listing danger signs—jaundice spreading to the arms or legs, poor feeding, lethargy, dark urine, pale stools—and instructing them to contact their midwife or GP if any appear. Some trusts have also launched smartphone apps that allow parents to upload a photo of their baby and receive an automated risk assessment based on skin colour. These tools are not a substitute for a bilirubin measurement, but they may help parents recognise when to seek help. The charity Bliss runs a campaign called "Spotting Jaundice" that provides free bilirubinometers to community midwives in areas with the lowest screening rates. Since 2022, they have distributed roughly 500 devices, and early data suggest that the programme has increased screening rates in participating trusts by an average of 25 percentage points.

What the Data Say About Implementation

Despite these efforts, implementation remains uneven. A 2024 survey of 200 community midwives conducted by the Royal College of Midwives found that 70% supported universal bilirubin screening in the community, but only 40% said they had access to a device. The main barriers cited were cost (55%), lack of training (30%), and concerns about device maintenance (15%). The NHS England target for 2028 is that 90% of newborns will receive a bilirubin measurement before day 5, with a particular focus on home births and early discharges. Current national data, from the Maternity Services Data Set, show that as of late 2024, the figure is around 72% nationally, with wide variation: Scotland leads at roughly 85%, while Wales lags at about 60%. In rural areas of England, such as Cornwall and Cumbria, the rate is estimated to be below 50%.

Cost is a recurring theme. A single handheld bilirubinometer costs around £400, and a trust with 50 community midwives would need to spend £20,000 to equip them all—not a huge sum in the context of a trust's overall budget, but a barrier in a system where community maternity budgets are often tight. Maintenance and calibration add ongoing costs. Some trusts have tried to save money by using a single device per team, but midwives report that sharing devices leads to low usage because the device is often not available when needed. There is also a debate about whether universal screening is always appropriate. Some clinicians argue that for low-risk, term infants born at home, the risk of severe jaundice is so low that visual assessment is sufficient. A 2023 commentary in the British Journal of Midwifery argued that routine bilirubin screening in the community could lead to over-referral and unnecessary treatment, increasing parental anxiety and healthcare costs. The authors noted that the number needed to screen to prevent one case of severe hyperbilirubinemia is estimated at roughly 2,000–5,000, depending on the population. Proponents of universal screening counter that the number needed to screen is similar to that for other routine newborn screening tests, such as hearing screening or the newborn blood spot test, and that the consequences of a missed case are severe. They also point out that visual assessment is not just inaccurate but systematically biased: darker-skinned infants are more likely to have their jaundice underestimated, contributing to racial disparities in outcomes.

A Practical Path Toward Equity

Closing the gap between hospital and community jaundice care will require a combination of investment, training, and standardisation. Several practical steps are already being taken. The NHS is developing a standardised protocol for community jaundice assessment that includes a mandatory bilirubin measurement at the first postnatal visit, with clear referral thresholds. The protocol is expected to be published in 2026 and will be incorporated into the NHS Standard Contract for maternity services. Shared decision-making with parents is also being emphasised. Some trusts now provide parents with a handout explaining the bilirubin measurement and what the number means, encouraging them to ask their midwife for a reading if one is not offered. This approach respects parental autonomy while promoting safety. Integration with existing home birth pathways is another priority. In areas where home birth is common, midwifery teams are being encouraged to carry bilirubinometers as standard equipment, alongside the blood pressure cuff and stethoscope. The Royal College of Midwives has recommended that all community midwives be issued a device by 2028, though funding remains uncertain. Regular audits of jaundice outcomes by setting would help identify disparities and track progress. Some trusts already audit readmission rates for jaundice by place of birth, but national-level data are not routinely published. The Maternity Services Data Set could be expanded to include bilirubin screening rates by setting, allowing commissioners to target resources where they are needed most.

Investment in portable screening tools is the most direct lever. At roughly £400 per device, the cost of equipping every community midwife in England would be roughly £4–5 million—a small fraction of the NHS's annual maternity budget. With savings from reduced readmissions and litigation, the investment would likely pay for itself within a few years. A similar argument could be made for Scotland, Wales, and Northern Ireland, where the numbers are smaller but the principle is the same. The gap between hospital and community jaundice care is not a story of bad clinicians or broken systems. It is a story of how evidence takes time to travel from the guideline to the bag. The tools exist. The evidence is clear. The remaining step is a coordinated effort to make them standard, not optional. For commissioners and policymakers, the question is: will the investment be made now to prevent preventable harm, or will the gap persist until the next high-profile case forces action?

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for concerns about neonatal jaundice.